Volitionrx Ltd

  • Health Care
  • Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • www.volition.com
  • Earnings Score
  • Safety Score
  • Market Cap $58.21M
  • Debt $5.77M
  • Cash $5.41M
  • EV $58.56M
  • FCF -$14.53M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$30.20M
EBIT-$29.98M
ROA-236%
FCF-$14.53M
Equity-$21.50M
Growth Stability1
PE-1.93
PB-2.71
P/FCF-4.01
P/S45.27
Price/Cash0.09
Debt/Equity-0.27
Debt/FCF-0.4
Net Margins-2K%
Op. Margins-2K%
Earnings CAGR-0%
Sales Growth YoY187%
Sales Growth QoQ20%
Sales CAGR18%
Equity CAGR2%
Earnings Stability0
Earnings Growth YoY-31%
Earnings Growth QoQ-17%
Sales CAGR 5Y209%
Equity CAGR 5Y-5%
Earnings CAGR 3Y144%
Sales CAGR 3Y144%
Equity CAGR 3Y-4%
Market Cap$58.21M
Revenue$1.29M
Assets$12.68M
Total Debt$5.77M
Cash$5.41M
Shares Outstanding92.39M
EV58.56M
Earnings Score6%
Safety Score33%
Working Capital-23.48M
Current Ratio0.22
Shares Growth 3y25%
Equity Growth QoQ-1%
Equity Growth YoY953%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
VolitionRX Ltd is a us-based multi-national life sciences company. It is engaged in developing easy to use blood-based tests to accurately diagnose a range of cancers. The development pipeline includes assays to be used for symptomatic patients or asymptomatic populations. The company has developed more than 30 blood-based assays to detect specific biomarkers. It also develops Nucleosomics tests for several major cancers including CRC, pancreatic, lung and aggressive prostate. In addition, the company engages in the process of developing HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to help decide the appropriate therapy.

SEC Filings

Direct access to Volitionrx Ltd (VNRX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Volitionrx Ltd compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Volitionrx Ltd compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -0%
Stability 0%
loading chart...

Volitionrx Ltd Discounted Cash Flow

Fully customizable DCF calculator online for Volitionrx Ltd.

= -$145M
012345678910TV
fcf-$15M-$15M-$15M-$15M-$15M-$15M-$15M-$15M-$15M-$15M-$15M-$145M
DCF-$13M-$12M-$11M-$9.9M-$9M-$8.2M-$7.5M-$6.8M-$6.2M-$5.6M-$56M
Value-$145M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins-132K%-----525K%-152K%-30K%-10K%-5K%-2K%
ROA--130%-50%-103%-102%-75%-81%-103%-174%-129%-236%
ROE-480%-193%-559%-148%-632%-125%-152%979%457%-

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF--0-0.05-0.13-0.19-0.29-0.23-0.18-0.29-0.32-0.4
Debt over Equity-00.020.180.230.250.260.22-1.57-0.77-0.27
Growth Stability----------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth-------21%570%240%153%209%
Earnings YoY growth--249%-241%36%-68%399%-77%32%13%17%-
Equity YoY growth-2K%250%-53%22%17%15%8%-118%150%-5%
FCF YoY growth-104%4%44%10%-19%51%19%-23%14%-